Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Customized |
Still deciding? Get samples of US$ 10/gram
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Chemical name: Selumetinib
MF: C17H15BrClFN4O3
MW: 457.685
CAS: 606143-52-6
Appearance: White powder
Purity: 99%
Package: 100g/foil bag
Selumetinib is an orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.
Selumetinib is under investigation for the treatment of Carcinoma, Thymic, Non-Small Cell Lung Cancer, and Carcinoma, Small Cell Lung. AZD6244 has been investigated for the treatment and basic science of Melanoma, Solid Tumours, Breast Cancer, Non Small Cell Lung Cancer, and Non Small Cell Lung Carcinoma, among others.